Tag: PrEP

Conversations That Matter – Sex Workers and PrEP at CAHR 2017

by Andrew Sorfleet

The possible unintended consequences of the introduction of PrEP to the sex industry is something that has been discussed in international sex work advocacy since at least 2012. So, when I saw that new PrEP prescription guidelines for Canada were being drafted, stating that “sex-trade workers” were a “significant risk of having transmissible HIV,” I was troubled that there had been no community consultation whatsoever. National guidelines required a national convening.

Women + PrEP: 5 Important Facts

By Molly Bannerman

The emergence of PrEP has highlighted important gender inequalities in HIV transmission and HIV prevention. PrEP, or pre-exposure prophylaxis, is a drug that HIV-negative people (including women!) can take to help prevent HIV; however, most discussions about PrEP focus on men. Despite representing fewer new HIV infections than men, women also need innovative HIV prevention methods.

Trois points à retenir de la Conférence AFRAVIH 2016

Par Gabriel Girard

Gabriel-Girard-690x447L’AFRAVIH est une conférence scientifique, organisée tous les deux ans par l’Alliance francophone des acteurs de santé contre le VIH. Elle avait lieu cette année du 20 au 23 avril à Bruxelles, rassemblant plus d’un millier de participants, venus d’Europe, d’Afrique, d’Asie ou d’Amérique du Nord. L’AFRAVIH ouvre un espace de débat francophone unique pour les acteurs de la lutte contre le VIH et les hépatites virales. La conférence est l’occasion de discuter avec des intervenants très divers, issus du milieu communautaire, de la recherche ou de la santé publique. Difficile de faire le tri dans un programme aussi riche[1]… Mais voici trois points à retenir de la conférence!

5 ways that PrEP highlights gender inequities in HIV

San PattenBy San Patten

One of the most memorable moments in my 20 years working in the HIV field happened in a standing-room-only meeting hall in Vienna at the International AIDS Conference in 2010. This was the moment that the clinical trial CAPRISA 004 announced proof-of-concept for prevention of HIV among women using a vaginal microbicide (1% tenofivir gel). The entire room broke out in a standing ovation and tears of joy. Finally! A prevention tool that could allow a woman to protect herself in sexual encounters, regardless of the desires and wishes of her sexual partner. Five years later, microbicides have not yet come to fruition. But pre-exposure prophylaxis (PrEP) holds the same great promise.